The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index; 3 of the 9 sources its claims cite were checked for support.
Raise standards for preclinical cancer research
Open accessOverview
CoChat Summary
TL;DR
This Nature Comment argues that many landmark preclinical oncology findings are not reproducible and calls for higher standards in methods, reporting, and incentives. It reports that Amgen confirmed only 6 of 53 landmark papers (11%) and cites Bayer’s finding that about 25% of published preclinical studies could be validated.
Key findings
- In Amgen’s ten-year retrospective analysis, scientific findings were confirmed in only 6 of 53 “landmark” preclinical cancer papers (11%); non-reproduced studies often lacked blinding, relied on single experiments such as one Western blot, or presented selected data.
- Bayer HealthCare reported that only about 25% of published preclinical studies could be validated to the point at which projects could continue; published cancer research represented 70% of the studies analysed in that report, with possible overlap with Amgen’s 53 papers.
- Citation data showed non-reproduced articles in journals with impact factor >20 had a mean of 248 citations (range 3–800) versus 231 (range 82–519) for reproduced articles; for impact factor 5–19, non-reproduced articles had a mean of 169 citations (range 6–1,909) versus 13 (range 3–24) for reproduced articles.
- The authors recommend reporting negative data, blinding preclinical experiments, validating reagents, repeating critical experiments, avoiding single cell lines or models, requiring patient-selection biomarkers, and changing academic incentives.
Methods
- This is a Nature Comment/perspective, not a primary experimental study; it synthesizes Amgen’s ten-year retrospective analysis of experiments performed prospectively and cites a Bayer HealthCare report.
- Amgen selected 53 “landmark” papers describing completely new approaches or alternative clinical uses, attempted confirmation, used additional models, contacted original authors, exchanged reagents, and repeated experiments under the authors’ direction, occasionally in the original investigator’s laboratory.
- The analysis reports counts of confirmed findings and citation metrics from Google Scholar, May 2011; the recommendations are proposed changes rather than tested interventions.
Limitations
- Stated: validation attempts may have failed because of technical differences or difficulties despite efforts to ensure otherwise; additional models were used; when findings could not be reproduced, authors were contacted and experiments were repeated under their direction.
- Stated: papers were deliberately selected as “landmark” and described something completely new, so some data might not hold up; Bayer’s analysed studies may overlap with Amgen’s 53 papers.
- Evident: as a Comment, the text provides no detailed systematic protocol, inclusion criteria, statistical methods, or full dataset; the citation analysis is descriptive and limited to two impact-factor strata.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 1 Not valid · 6 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sadly, clinical trials in oncology have the highest failure rate compared with other therapeutic areas.”
What the sources say
- Partly supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). sourceExperimental — accuracy not yet measured
The opening passage of our copy (labelled Abstract; page unavailable) says cancer-drug attrition is much higher than in other therapeutic areas, citing 5% of anticancer agents versus 20% of cardiovascular agents reaching licensure. That comparison covers development from preclinical activity through phase III, not failure rates specifically among clinical trials; it also does not explicitly establish a highest-rate ranking. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low 1 .”
What the sources say
- Supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). source
The opening passage (labeled Abstract in our copy; no page given) reports that only 5% of agents with preclinical anticancer activity are licensed after demonstrating sufficient efficacy in phase III testing. It also says cancer drug attrition is much higher than in other therapeutic areas, supporting the claim of historically low translation to clinical success. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies for which findings could be reproduced, authors had paid close attention to controls, reagents, investigator bias and describing the complete data set.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For results that could not be reproduced, however, data were not routinely analysed by investigators blinded to the experimental versus control groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators frequently presented the results of one experiment, such as a single Western-blot analysis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 22 claims and every source verdict.
- It may state two separate claims as one. 2
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there are other more common sources of unreliability in the literature (41)(42)(43)(44)”
From Misconduct accounts for the majority of retracted scientific publications (2012) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many established scientific results in the social (49, 50) and biomedical (51-53) sciences cannot readily be replicated.”
From Misinformation in and about science (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A landmark study conducted by Glenn Begley and his team in 2012 concluded that most cancer research studies were not reproducible, by alarmingly reporting that 47 of 53 published findings could not be replicated [13].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cell biology, two industrial laboratories reported success replicating the original results of landmark findings in only 11% and 25% of the attempted cases ( 10, 11 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Concerns about reproducibility are widespread across disciplines ( 921 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
Fanelli, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010271 · Cited by 805
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Raising the bar for cancer therapy models
Francia, G., & Kerbel, R. S. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-561 · Cited by 54
Cited by
Estimating the reproducibility of psychological science
Open Science Collaboration (2015) · Science · doi:10.1126/science.aac4716 · Cited by 8,515
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Power failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000410 · Cited by 5,939
1,500 scientists lift the lid on reproducibility
Baker, M. (2016) · Nature · doi:10.1038/533452a · Cited by 4,209
Metadata
- Authors
- Begley, C. G., & Ellis, L. M.
- Affiliations
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Ellis, Lee M.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 531-533
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987777080
- Semantic Scholar
- 1a81d3d1e8a983e0551edf485f4ac1a8cdd7fea4
- Cited by
- 2,979
- References
- 5
- Citations by year
- 2026: 106 · 2025: 116 · 2024: 127 · 2023: 169 · 2022: 179 · 2021: 206 · 2020: 236 · 2019: 255 · 2018: 262 · 2017: 271 · 2016: 283 · 2015: 262 · 2014: 226 · 2013: 133 · 2012: 62
- FWCI
- 210.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2012-05-02)
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- preclinical cancer research, research standards, publication practices, research incentives, translational research, clinical trials
- MeSH terms
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Research Design, Reproducibility of Results, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Raise standards for preclinical cancer research. https://app.cochat.ai/papers/10.1038/483531a
- The paper
- Begley, C. G., & Ellis, L. M. (2012). Raise standards for preclinical cancer research. Nature. https://doi.org/10.1038/483531a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.